Clinical efficacy of peptide receptor radionuclide therapy with radiolabelled somatostatin analogues (PRRT) of metastatic neuroendocrine tumours (NETs) – A single-centre cohort study

#4333

Introduction: PRRT is indicated for disease progression in patients with disseminated or unresectable NETs, especially those originating from the midgut. Up to date clinical trials have proven the efficacy of PRRT in gastrointestinal NETs, while data on other localisations are limited.

Aim(s): Evaluation of the effectiveness of PRRT in patients with metastatic NETs of different origin.

Materials and methods: Retrospective analysis of PRRT administered from 2010 to 2021. Post-treatment tumour response was assessed according to RECIST 1.1. Kaplan-Meier analysis and log-rank tests were used to analyse PFS and OS.

Conference:

Presenting Author:

Authors: Hamm M, Kropinska A, Handkiewicz-Junak D, Ledwon A, Paliczka-Cieslik E,

Keywords: PRRT, NET, gastrointestinal, pancreatic, bronchopulmonary, FPI,